evalu
photochem
treatment
process
inactiv
parvoviru
lack
simpl
cultur
method
measur
infect
recent
develop
enzymelink
immunospot
elispot
infect
assay
use
latestag
erythropoiet
progenitor
cell
labor
intens
time
consum
evalu
novel
effici
polymeras
chain
reaction
pcr
inhibit
assay
examin
correl
reduct
infect
method
contamin
plasma
treat
mmoll
amotosalen
jcm
ultraviolet
light
test
dna
modif
use
convent
pcr
inhibit
novel
preamplif
approach
novel
assay
subject
sampl
preamplif
cycl
use
longtempl
pcr
follow
quantit
pcr
qpcr
inhibit
detect
approach
test
correl
reduct
viral
infect
compar
elispot
assay
result
ident
sampl
result
preamplif
inhibit
assay
show
detect
rang
log
demonstr
quantit
correl
reduct
viral
infect
elispot
result
convent
pcr
detect
log
reduct
amplif
correl
reduct
viral
infect
rang
inhibit
hepat
b
viru
dna
amplif
also
achiev
conclus
result
demonstr
novel
preamplif
qpcr
assay
use
tool
predict
reduct
infect
photochem
treatment
assay
extend
show
util
circumst
practic
vitro
assay
unavail
determin
efficaci
pathogen
inactiv
human
parvoviru
nonenvelop
singlestrand
dna
viru
transmit
primarili
respiratori
rout
also
bloodcom
ponent
transfus
transfusiontransmit
infect
immunocompet
individu
clinic
mild
asymptomat
persist
howev
infect
caus
seriou
diseas
acut
chronic
anemia
immunocompromis
patient
fetal
hydrop
spontan
abort
pregnant
women
also
provok
persist
complic
patient
hematolog
problem
requir
initi
receiv
blood
transfus
risk
transmiss
transfus
increas
season
high
viral
titer
infect
donor
donat
pool
viral
resist
current
inactiv
method
current
bloodsafeti
practic
screen
donat
routin
us
food
drug
administr
requir
place
estim
make
screen
discard
blood
product
impract
present
pathogeninactiv
method
implement
ineffect
highli
resili
viru
withstand
virucid
process
heat
denatur
solventdeterg
treatment
effect
lipidenvelop
virus
prevent
transfusiontransmit
infect
new
pathogeninactiv
method
capabl
penetr
tight
capsid
inhibit
replic
function
requir
intercept
blood
system
photochem
treatment
pct
process
use
amotosalenhcl
uv
light
uva
develop
inactiv
virus
bacteria
protozoa
leukocyt
platelet
plasma
transfus
inactiv
mechan
combin
nucleic
acidintercal
properti
amotosalen
crosslink
capabl
uva
activ
elimin
replic
function
treat
pathogen
pct
shown
inactiv
broad
spectrum
virus
bacteria
parasit
white
blood
cell
creat
safer
bloodtransfus
product
studi
efficaci
inactiv
pct
effici
straightforward
vitro
assay
correl
infect
lack
present
assay
determin
inactiv
limit
vari
sensit
detect
abil
instanc
genom
equival
geq
method
measur
small
portion
viral
genom
via
polymeras
chain
reaction
pcr
determin
geq
titer
incomplet
alter
viral
particl
although
render
noninfecti
could
potenti
result
posit
geq
artifici
increas
viral
titer
avail
use
fulllength
genom
pcr
primer
would
remedi
problem
howev
pcr
quantit
biolog
assay
although
abl
measur
infecti
titer
time
consum
labor
intens
limit
assay
volum
take
consider
shortcom
assay
develop
new
quantit
pcr
qpcr
test
viral
replic
function
demonstr
effect
pct
rather
measur
rel
presenc
parent
dna
assay
measur
replic
abil
inactiv
parent
dna
compar
similarli
preamplifi
untreat
treat
viral
prepar
use
qpcr
inhibit
preamplif
level
baselin
control
would
demonstr
complet
inactiv
viru
assay
easi
simpl
perform
demonstr
strong
correl
infect
combin
result
infect
assay
fulllength
pcr
amplif
novel
assay
preamplif
qpcr
demonstr
log
inactiv
pct
furthermor
qpcr
assay
use
preamplif
pcr
inhibit
appli
futur
investig
pathogen
inactiv
plasma
obtain
grifol
baxter
hepat
b
viru
hbv
infect
plasma
sampl
collect
komfo
anoky
teach
hospit
kumasi
ghana
report
elsewher
pcr
reagent
obtain
appli
biosystem
unless
otherwis
note
prepar
sampl
untreat
infect
sampl
use
control
infect
platelet
concentr
creat
resuspend
platelet
plasma
pct
pct
platelet
plasma
perform
use
condit
use
intercept
blood
system
baxter
healthcar
briefli
platelet
plasma
treat
mmol
l
amotosalen
jcm
uva
viral
dna
extract
preamplif
inhibit
assay
viral
dna
extract
ml
plasma
use
high
pure
viral
nucleic
acid
kit
roch
diagnost
accord
manufactur
instruct
sampl
high
viral
load
dilut
use
virusneg
plasma
perform
extract
final
concentr
nucleic
acid
within
dynam
rang
qpcr
studi
semiquantit
pcr
dna
extract
infect
plasma
excis
restrict
enzym
xhoi
kpni
result
fragment
devoid
viral
invertedrepeat
region
insert
pbluescriptii
sk
plasmid
bp
result
plasmid
kb
size
solut
log
copiesml
use
stock
solut
analysi
perform
control
pcttreat
sampl
primer
sequenc
amplifi
templat
follow
nt
forward
nt
revers
reaction
contain
pcr
buffer
mmoll
dntp
mmoll
mgcl
mmol
l
primer
dimethyl
sulfoxid
ml
dna
templat
uml
taq
dna
polymeras
pcr
paramet
min
cycl
min
min
preamplif
hbv
preamplif
perform
control
pcttreat
sampl
viral
dna
amplifi
use
primer
span
region
suffici
conserv
across
genotyp
forward
bp
pcr
mixtur
contain
pcr
buffer
ii
mmol
l
mgcl
mmoll
dntp
mmoll
primer
u
amplitaq
dna
polymeras
ml
templat
dna
contain
copiesml
use
reaction
pcr
paramet
pcr
initi
incub
min
cycl
min
follow
cycl
min
perform
pcr
gener
bp
cycl
min
use
gener
bp
cycl
min
use
gener
bp
cycl
min
perform
pcr
follow
incub
min
hbv
pcr
paramet
pcr
initi
incub
cycl
preamplif
appli
min
min
increment
everi
cycl
final
step
min
reaction
gener
amplicon
condit
appli
cycl
without
time
increment
amplicon
cycl
preamplif
appli
qpcr
condit
hbv
preamplif
sampl
quantifi
term
intern
unit
per
millilit
use
realtim
pcr
viral
dna
quantifi
use
multiplex
qpcr
system
stratagen
taqmanbas
technolog
method
describ
elsewher
primer
qpcr
bp
design
basi
sequenc
within
gene
primer
hbv
qpcr
bp
nt
forward
nt
revers
taqman
probe
hbv
nt
forward
hbv
nt
revers
hbv
taqman
probe
fluorogen
probe
label
vic
appli
biosystem
label
amplif
perform
duplic
use
brilliant
qpcr
core
reagent
kit
stratagen
accord
manufactur
instruct
initi
incub
min
cycl
min
perform
duplic
serial
dilut
first
intern
standard
parvoviru
dna
nat
assay
nation
institut
biolog
standard
control
nibsc
iu
genomereact
use
refer
curv
quantif
hbv
qpcr
perform
cycl
standard
quantif
intern
unit
per
millilit
nibsc
four
serial
dilut
made
refer
curv
enzymelink
immunospot
elispot
assay
determin
infect
plasma
platelet
evalu
infect
describ
elsewher
briefli
viabl
viru
titer
determin
infect
cell
cell
cell
induc
differenti
cell
infect
serial
dilut
control
pct
sampl
transfer
elispot
plate
coat
polyclon
antibodi
protein
dako
elispot
plate
incub
h
cell
wash
bound
antigen
detect
develop
silver
stain
visual
plate
reader
count
data
analysi
elispot
assay
observ
viral
infect
titer
use
calcul
log
number
inactiv
viru
pct
spotform
unit
calcul
follow
total
number
spot
observ
well
divid
dilut
divid
volum
materi
plate
dilut
log
reduct
analyz
log
control
treat
determin
extent
pcr
inhibit
result
photochem
treatment
amotosalen
mmoll
uva
jcm
dose
pct
semiquantit
pcr
use
establish
detect
sensit
measur
effect
pct
figur
pcr
approach
appli
condit
amplif
nucleicacid
fragment
long
enough
amplicon
detect
modif
viral
genom
caus
pct
rang
sensit
log
accuraci
differ
standard
use
demonstr
assay
rang
standard
subject
amplif
long
amplicon
use
detect
postpct
pcr
product
densitometri
band
show
correl
band
intens
concentr
amplifi
templat
figur
standard
base
pcr
increas
input
titer
genom
plasmid
plasmid
encod
entir
genom
minu
invertedrepeat
region
basi
standard
lower
limit
sensit
assay
log
copi
demonstr
detect
amplifi
band
input
titer
log
copi
figur
lane
b
densitometri
dna
gel
show
amplifi
signal
becam
stronger
increas
amount
electrophoresi
agaros
gel
contain
ethidium
bromid
gml
use
visual
pcr
product
amplifi
genom
arrow
log
titer
shown
gel
correspond
integr
densiti
band
pcr
use
serial
dilut
plasmid
contain
genom
rang
detect
densitometri
seen
log
titer
calcul
basi
dna
concentr
determin
spectrophotometri
b
pcr
use
serial
dilut
untreat
viral
extract
lane
af
stock
titer
genom
equivalentsml
untreat
control
determin
quantit
pcr
assay
bp
pcr
sensit
amplicon
lower
rang
detect
densitometri
seen
howev
inactiv
demonstr
highest
titrat
sampl
pct
limit
detect
figur
preamplif
condit
quantit
polymeras
chain
reaction
qpcr
rang
detect
inhibit
parvoviru
amplif
plasma
cycl
use
preamplif
preamp
respect
amplicon
length
longer
amplicon
cycl
need
gener
copi
b
valid
assay
determin
lograng
sensit
qpcr
perform
preamp
control
determin
log
rang
assay
confirm
equal
amount
dna
product
produc
preamplif
condit
preamp
subject
preamp
constitut
baselin
control
consist
qpcr
amplicon
preamp
product
amplicon
length
show
rang
amplif
rang
within
one
detect
inhibit
photochem
treatment
preamplif
control
product
equal
copi
pcr
c
cycl
threshold
input
reach
plateau
input
titer
log
figur
lane
f
higher
input
titer
log
result
increas
densitometri
dna
band
compar
input
band
figur
lane
g
h
demonstr
linear
dynam
rang
figur
lane
af
corrobor
log
rang
shown
plasmid
rel
rang
detect
also
demonstr
use
untreat
viral
extract
shown
increas
input
titer
figur
lowest
concentr
detect
correspond
input
titer
log
viral
extract
subject
pct
assess
effect
amplif
figur
lane
af
show
untreat
viral
extract
compar
lane
gl
lane
l
depict
undilut
pct
viral
extract
demonstr
pct
caus
complet
pcr
inhibit
detect
band
pct
lane
amplif
demonstr
reduct
genom
convent
pcr
approach
demonstr
compar
method
detect
chang
signal
amplif
viral
sampl
treat
pct
versu
untreat
control
sampl
lack
quantit
analysi
measur
pcr
inhibit
pct
convent
realtim
qpcr
unsuccess
inabl
assay
support
long
amplicon
modifi
approach
involv
preamplif
larg
pcr
product
follow
qpcr
short
amplicon
develop
detect
inactiv
pct
purpos
combin
use
longtempl
pcr
amplicon
accur
detect
whether
dna
adduct
form
viral
genom
quantit
method
compar
differ
untreat
pct
sampl
figur
list
preamplif
condit
accord
amplicon
size
cycl
number
preamplif
pcr
increas
viral
inactiv
shown
use
preamplif
polymeras
chain
reaction
pcr
enzymelink
immunospot
elispot
assay
log
inhibit
increas
exposur
time
amotosalen
uva
treatment
preamplif
pcr
log
inhibit
result
averag
result
use
preamplif
amplicon
sampl
subject
elispot
measur
log
reduct
infect
b
strong
correl
preamplif
pcr
assay
elispot
repres
direct
plot
result
assay
calcul
r
valu
condit
sever
amplicon
length
vari
bp
kb
adjust
gener
equal
amount
final
pcr
product
measur
use
short
qpcr
amplicon
bp
qpcr
standard
curv
preamplif
product
demonstr
accur
normal
preamplif
condit
compar
preamplif
control
qpcr
baselin
control
preamplif
figur
show
case
preamplif
condit
creat
rang
preamplif
compar
baselin
control
pcr
amplif
plasma
inhibit
pct
preamplif
qpcr
assay
detect
inhibit
viral
amplif
pct
limit
detect
figur
log
inhibit
amplif
increas
longer
amplicon
demonstr
need
preamplif
step
amplicon
kb
detect
maximum
effect
pct
amplicon
compar
evalu
pct
inactiv
dna
modif
genom
caus
pct
correl
viral
replic
function
demonstr
quantit
approach
measur
pathogen
inactiv
increas
efficaci
amotosalen
plasma
preincub
nonenvelop
viru
preincub
viru
amotosalen
could
increas
drug
exposur
avail
viral
genom
time
cours
increas
incub
period
amotosalen
uva
illumin
show
log
inhibit
amplif
reduct
infect
could
improv
longer
preincub
figur
illustr
correl
result
assay
plot
figur
r
graph
illustr
strong
correl
result
show
potenti
use
preamplif
qpcr
assay
extrapol
reduct
viral
infect
exampl
use
assay
log
inhibit
measur
qpcr
inhibit
correspond
log
reduct
infect
measur
elispot
effort
determin
whether
preamplif
pcr
assay
could
detect
inhibit
presenc
cellular
compon
inactiv
studi
figur
platelet
concentr
plasma
pct
inhibit
amplif
platelet
log
effect
increas
preincub
contamin
plasma
amotosalen
uva
similar
result
plasma
demonstr
correl
preamplif
pcr
assay
infect
result
sampl
measur
assay
directli
compar
r
valu
corrobor
result
pct
plasma
strong
correl
elispot
preamplifi
figur
preincub
parvoviru
contamin
platelet
amotosalen
measur
preamplif
polymeras
chain
reaction
pcr
enzymelink
immunospot
elispot
assay
log
inhibit
platelet
concentr
increas
exposur
time
amotosalen
uv
light
uva
treatment
preamplif
pcr
log
inhibit
result
averag
result
use
preamplif
amplicon
sampl
subject
elispot
measur
log
reduct
infect
b
strong
correl
preamplif
pcr
elispot
assay
repres
direct
plot
result
assay
figur
preamplif
condit
quantit
polymeras
chain
reaction
qpcr
rang
detect
inhibit
hepat
b
viru
hbv
amplif
plasma
cycl
use
preamplif
preamp
respect
amplicon
length
longer
amplicon
cycl
need
gener
copi
b
valid
assay
determin
log
rang
sensit
hbv
control
qpcr
confirm
equal
amount
dna
product
produc
preamp
condit
preamp
subject
preamp
constitut
baselin
control
consist
qpcr
amplicon
preamp
product
amplicon
length
show
rang
amplif
broader
log
rang
attribut
increas
preamp
cycl
number
use
hbv
assay
c
cycl
threshold
cation
pcr
inhibit
assay
case
preamplif
pcr
log
inhibit
would
equal
reduct
infect
log
preamplif
pcr
inhibit
assay
measur
inactiv
hbv
pct
assay
develop
extend
pathogen
vitro
test
exist
hbv
use
model
determin
whether
assay
could
also
detect
efficaci
pct
hbvcontamin
plasma
whether
improv
could
made
dynam
rang
assay
figur
show
preamplif
condit
amplicon
size
number
cycl
illustr
number
preamplif
cycl
directli
determin
rang
log
inhibit
possibl
control
perform
measur
dynam
rang
test
hbv
amplif
hbv
primer
gener
amplicon
increas
length
preamplif
pcr
condit
normal
produc
number
copi
figur
case
hbv
preamplif
cycl
normal
cycl
amplicon
mathemat
preamplif
cycl
assumpt
effici
would
yield
copi
equal
log
practic
effici
pcr
reach
control
show
rang
log
inhibit
log
therefor
maximum
log
inhibit
hbv
broader
rang
detect
possibl
condit
set
hbv
set
increas
number
preamplif
cycl
inhibit
hbv
amplif
limit
detect
pct
preamplif
pcr
assay
develop
hbv
use
figur
treatment
sampl
pct
caus
inhibit
amplif
limit
detect
log
graph
show
amplicon
length
kb
necessari
detect
effect
pct
develop
pathogeninactiv
method
blood
product
would
allow
safer
blood
transfus
present
blood
bank
test
presenc
specif
pathogen
figur
photochem
treatment
inhibit
hepat
b
viru
amplif
plasma
use
preamplif
quantit
polymeras
chain
reaction
assay
graph
show
increas
preamplif
amplicon
length
greater
amount
log
inhibit
detect
amplicon
length
kb
requir
detect
full
log
inhibit
assay
test
limit
detect
avail
sensit
time
requir
product
releas
use
pathogen
inactiv
would
provid
ideal
scenario
broad
spectrum
bacteria
virus
parasit
could
inactiv
fewer
blood
product
would
wast
establish
effect
pathogeninactiv
technolog
biolog
assay
standard
determin
reduct
infecti
titer
pathogen
test
system
current
avail
frequent
limit
complic
biolog
assay
time
consum
labor
intens
pathogen
vitro
assay
exist
present
studi
develop
novel
preamplif
qpcr
inhibit
assay
use
estim
reduct
viral
infect
parallel
associ
pcr
amplif
infect
appli
inactiv
studi
differ
virus
equat
result
particular
assay
result
anoth
assay
pcr
assay
allow
quicker
result
determin
presenc
pathogen
sampl
also
measur
amplif
capabl
pathogen
inactiv
determin
whether
treatment
disrupt
replic
function
viru
use
faster
moreeffici
test
method
one
also
studi
close
biolog
capabl
viru
capsid
penetr
dose
effect
preincub
paramet
optim
assay
analysi
vari
length
pcr
product
determin
amplicon
size
necessari
detect
pct
inactiv
amplicon
length
increas
preamplif
cycl
necessari
produc
equal
number
copi
decreas
replic
effici
longer
pcr
product
normal
preamplif
reaction
allow
direct
comparison
amplicon
length
determin
condit
best
suit
studi
pathogen
inactiv
pct
introduc
preamplif
qpcr
inhibit
assay
potenti
inactiv
test
studi
also
reveal
way
improv
assay
increas
sensit
rang
exampl
increas
number
preamplif
cycl
would
broaden
log
sensit
assay
demonstr
use
condit
appli
detect
hbv
inhibit
compar
amount
parent
dna
baselin
increas
amplif
rang
would
provid
greater
potenti
detect
finer
differ
control
pct
sampl
mathemat
true
preamplif
condit
normal
equal
smallest
amplicon
subject
preamplif
cycl
preamplif
cycl
hbv
assumpt
pcr
effici
preamplif
cycl
increas
copi
number
amplicon
log
preamplif
cycl
assumpt
effici
would
yield
copi
log
case
hbv
pcr
effici
therefor
log
rang
log
perfect
imposit
preamplif
product
viru
show
pcr
effici
decreas
increas
amplicon
size
thu
maintain
preamplif
rang
cycl
need
amplicon
amplicon
amplicon
control
establish
rang
log
inhibit
assay
therefor
log
inhibit
amplif
log
pcttreat
plasma
sampl
would
demonstr
complet
inactiv
limit
detect
anoth
method
increas
detect
rang
assay
shift
baselin
curv
qpcr
amplicon
detect
preamplif
differ
control
pct
sampl
typic
small
bp
qpcr
step
amplifi
parent
dna
regardless
whether
crosslink
anoth
region
genom
statist
pct
caus
crosslink
everi
bp
thu
likelihood
qpcr
primer
amplifi
region
lack
adduct
high
therefor
although
parent
dna
crosslink
pct
qpcr
assay
fail
detect
use
longer
qpcr
target
would
decreas
statist
occurr
primer
amplifi
chanc
region
adduct
would
improv
assay
increas
log
rang
inactiv
possibl
without
increas
number
preamplif
cycl
result
preamplif
qpcr
assay
correl
elispot
assay
plasma
platelet
signifi
predict
infect
linear
relationship
identifi
use
assay
measur
effect
min
preincub
amotosalen
illumin
uva
instanc
preamplif
qpcr
inhibit
equival
reduct
infect
establish
refer
curv
qpcr
infect
one
extrapol
level
inactiv
infect
perform
qpcr
assay
conclus
novel
pcr
inhibit
assay
effect
demonstr
pct
inactiv
hbv
blood
product
